ROCKVILLE, Md., Jan. 29, 2020 /PRNewswire/ -- REGENXBIO Inc.
(Nasdaq: RGNX), a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy based on its proprietary NAV® Technology
Platform, today announced several poster presentations, including
interim data from its Phase I/II trial of RGX-121 for the treatment
of Mucopolysaccharidosis Type II (MPS II) and family surveys
focused on patients with neuronal ceroid lipofuscinosis type 2
(CLN2) disease, will be presented at the 16th Annual
WORLDSymposium™, taking place from February 10-13, 2020, in Orlando, FL.
The posters will be presented as follows:
Abstract Title: RGX-121 Gene Therapy for Severe MPS II
(Hunter Syndrome): Interim Results
of an Ongoing First in Human Trial (poster #LB-13)
Date/Time: Wednesday, February 12,
2020, from 4:30 to 6:30 p.m.
ET
Abstract Title: Family survey results of 7 children with
atypical neuronal ceroid lipofuscinosis type 2
(CLN2) disease in the United
States (poster #344)
Date/Time: Wednesday, February 12,
2020, from 4:30 to 6:30 p.m.
ET
Abstract Title: Results of a family survey on healthcare
resource needs in children with neuronal
ceroid lipofuscinosis type 2 (CLN2) disease in the US and
Canada (poster #345)
Date/Time: Wednesday, February 12,
2020, from 4:30 to 6:30 p.m.
ET
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates in
multiple therapeutic areas.
Contacts:
Tricia
Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
Heather Savelle, 212-600-1902
heather@argotpartners.com
Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-16th-annual-worldsymposium-2020-300994798.html
SOURCE REGENXBIO Inc.